martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 12, 2026

Is It Really Safe to Invest in AI Stocks and ETFs Right Now? Here's What the Experts Say.

View original at nasdaq.com
Is It Really Safe to Invest in AI Stocks and ETFs Right Now? Here's What the Experts Say. Key Points AI stocks have come under recent pressure amid concerns about spending…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • This capex growth is supported by a combination of AI agent adoption, token growth, and current market supply constraints

    60% confidence
  • According to a survey done before the start of the year, 90% of investors polled planned to hold or buy more AI stocks this year, and only 7% planned to decrease their exposure

    60% confidence
  • Recommends the Vanguard S&P 500 ETF as a core holding investors can consistently dollar-cost average into, alongside AI leaders Nvidia, Alphabet, Meta Platforms, AMD, Broadcom, and TSMC for long-term holding

    60% confidence
  • Computing demand is so strong that the economics of providing this computing power to third parties can be more attractive than for internal projects

    60% confidence
  • Raised 2026 capex guidance to $52-56 billion after extensive diligence talking to his own customers and his customers' clients, expressing confidence in continued AI chip demand

    60% confidence
  • AI data center capex is expected to grow by another 40% to 50% next year, bringing it to around $1.5 trillion

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Is It Really Safe to Invest in AI Stocks and ETFs Right Now? Here's What the Experts Say. — Source | Via News | es.VIA.NEWS